Consensus on breast cancer cell lines classification for an effective and efficient clinical decision-making

- Milioli, H. H., Tishchenko, I., Riveros, C., Sakoff, J., Berretta, R., Moscato, P.

Immunotherapy of distant metastatic disease

- Schadendorf, D., Algarra, S. M., Schachter, J., Hersey, P., Bastholt, L., Cinat, G., Dreno, B., Eggermont, A. M. M., Espinosa, E., Guo, J., Hauschild, A., Petrella, T.

The sequential use of endocrine treatment for advanced breast cancer: where are we?

- Barrios, C., Forbes, J. F., Hudis, C., Robertson, J. F. R., Jonat, W., Conte, P., Gradishar, W., Buzdar, A., Gelmon, K., Gnant, M., Bonneterre, J., Toi, M.

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT

- Regan, M. M., Walley, B. A., Spazzapan, S., Parmer, V., Ruhstaller, T., Abdi, E. A., Gelber, R. D., Coates, A. S., Goldhirsch, A., Pagani, O., Francis, P. A., Fleming, G. F., Lang, I., Gomez, H. L., Colleoni, M., Tondini, C., Pinotti, G., Salim, M.

Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer

- Green, M. D., Francis, P. A., Gebski, V., Harvey, V., Karapetis, C., Chan, A., Snyder, R., Fong, A., Basser, R., Forbes, J. F., Australian New Zealand Breast Cancer Trials Group

Regulation of PD-L1: a novel role of pro-survival signalling in cancer

- Chen, J., Jiang, C. C., Jin, L., Zhang, X. D.

Utility of adjuvant systemic therapy in melanoma

- Eggermont, A. M. M., Testori, A., Marsden, J., Hersey, P., Quirt, I., Petrella, T., Gogas, H., Mackie, R. M., Hauschild, A.

Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an international breast cancer study group report

- Karlsson, P., Cole, B. F., Forbes, J. F., Gelber, R. D., Goldhirsch, A., Gruber, G., Chua, B. H., Price, K. N., Lindtner, J., Collins, J. P., Kovacs, A., Thurlimann, B., Crivellari, D., Castiglione-Gertsch, M.

Which patients benefit most from adjuvant aromatase inhibitors?: results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

- Viale, G., Regan, M. M., Lang, I., Thürlimann, B., Mouridsen, H., Mauriac, L., Gelber, R. D., Price, K. N., Goldhirsch, A., Gusterson, B. A., Coates, A. S., Dell'Orto, P., Mastropasqua, M. G., Maiorano, E., Rasmussen, B. B., MacGrogan, G., Forbes, J. F., Paridaens, R. J., Colleoni, M.

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

- Coleman, R., de Boer, R., Frassoldati, A., Campbell, I., Paija, O., Martin, N., Modi, A., Bundred, N., Eidtmann, H., Llombart, A., Davidson, N., Neven, P., von Minckwitz, G., Sleeboom, H. P., Forbes, J., Barrios, C.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

- Rabaglio, M., Sun, Z., Colleoni, M., Pienkowski, T., Nogaret, J. -M., Láng, I., Smith, I., Gelber, R. D., Goldhirsch, A., Coates, A. S., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J. F., Paridaens, R. J.

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013

- Goldhirsch, A., Winer, E. P., Bonnefoi, Hervé, Bretel-Morales, Denisse, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Colleoni, Marco, Costa, Alberto, Curigliano, Giuseppe, Davidson, Nancy E., Leo, Angelo Di, Coates, A. S., Ejlertsen, Bent, Forbes, John F., Gelber, Richard D., Gnat, Michael, Goldhirsch, Aron, Goodwin, Pamela, Goss, Paul E., Harris, Jay R., Hayes, Daniel F., Hudis, Clifford A., Gelber, R. D., Ingle, James N., Jassem, Jacek, Jiang, Zefei, Karlsson, Per, Loibl, Sibylle, Morrow, Monica, Namer, Moise, Osborne, C. Kent, Partridge , Ann H., Penault-Llorca, Fréderiqué, Piccart-Gebhart, M., Perou, Charles M., Piccart-Gebhart, Martine, Pritchard, Kathleen I., Rutgers, Emiel J. T., Sedlmayer, Felix, Semiglazov, Vladimir, Shao, Zhi-Ming, Smith, Ian, Thürlimann, Beat, Toi, Masakazu, Tutt, Andrew, Untch, Michael, Viale, Giuseppe, Watanabe, Toru, Wilcken, Nicholas, Winer, Eric P., Wood, William C., Senn, H. - J., Albain, Kathy S., André, Fabrice, Bergh, Jonas

Agreement between HADS classifications and single-item screening questions for anxiety and depression: a cross-sectional survey of cancer patients

- Mackenzie, L. J., Carey, M. L., Sanson-Fisher, R. W., D'Este, C. A., Paul, C. L., Yoong, S. L.

Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015

- Coates, A. S., Winer, E. P., Bergh, Jonas, Bonnefoi, Hervé, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Colleoni, Marco, Curigliano, Giuseppe, Davidson, Nancy E., Leo, Angelo Di, Ejlertsen, Bent, Goldhirsch, A., Forbes, John F., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., André, Fabrice, Baselga, José

Biomarkers in melanoma

- Gogas, H., Eggermont, A. M. M., Hauschild, A., Hersey, P., Mohr, P., Schadendorf, D., Spatz, A., Dummer, R.

Small molecules and targeted therapies in distant metastatic disease

- Hersey, P., Bastholt, L., Schadendorf, D., Chiarion-Sileni, V., Cinat, G., Dummer, R., Eggermont, A. M. M., Espinosa, E., Hauschild, A., Quirt, I., Robert, C.

Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study

- Folprecht, G., Pericay, C., Ackland, S. P., Swinson, D., Kopp, M., Udovitsa, D., Hall, M., Iveson, T., Vogel, A., Zalcberg, J. R., Saunders, M. P., Thomas, A., Lopez Lopez, R., Roh, J. K., Chistyakov, V., Höhler, T., Kim, J. - S., Hofheinz, R. D.

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptorpositive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial

- Zdenkowski, N., Forbes, J. F., Mann, G. B., Coates, A. S., Gebski, V., Davies, L., Thornton, R., Reaby, L., Cuzick, J., Green, M., Boyle, F. M., Kannourakis, G., Gill, P. G., Bayliss, E., Saunders, C., Della-Fiorentina, S., Kling, N., Campbell, I.

Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial

- Barbour, A. P., Walpole, E. T., Mai, G. T., Barnes, E. H., Watson, D. I., Ackland, S. P., Martin, J. M., Burge, M., Finch, R., Karapetis, C. S., Shannon, J., Nott, L. M., Varma, S., Marx, G., Falk, G. L., Gebski, V., Oostendorp, M., Wilson, K., Thomas, J., Lampe, G.